Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone.
In vivo and in vitro experiments were conducted in an effort to elucidate the mechanism of suppression by halofuginone of skin strength in broilers. In the in vivo study, halofuginone was included at concentrations of 0, 1.5, 3, and 6 mg/kg of diet, corresponding to 0, 50, 100, and 200%, respectively, of the amount recommended for use as a coccidiostat. Each dietary treatment was given to 260 female broiler day-old chickens. Skin tearing was evaluated at the processing plant. Skin collagen and Kjeldahl-nitrogen were determined chemically. At the age of 7 wk, BW and feed efficiency were affected only in birds consuming the diet containing the highest concentration of the drug. Skin tearing increased but skin collagen concentration decreased in a dose-dependent manner. Fibroblasts were obtained by collagenase digestion from chicken skin and cultured. The cultured cells were incubated with various concentrations of halofuginone, monensin, and nicarbazin, and [3H]proline incorporation was evaluated in collagenase-digestible (representing mostly collagen) and nondigestible proteins exported by the cells into the medium. Halofuginone, at a concentration as low as 10(-11) M, inhibited incorporation of [3H]proline into collagenase-digestible proteins, but did not affect incorporation of [3H]proline into collagenase-nondigestible proteins. Even at concentrations as high as 10(-9) M, neither monensin nor nicarbazin affected collagenase-digestible proteins. The in vitro results suggest that halofuginone specifically inhibits collagen synthesis by skin fibroblasts. Results of both in vivo and in vitro trials suggest that the increase of skin tearing during processing, induced by halofuginone, is caused by direct suppression of skin collagen synthesis.
Granot
I
I
Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Isreal.
Bartov
I
I
Plavnik
I
I
Wax
E
E
Hurwitz
S
S
Pines
M
M
D000818:Animals; D002478:Cells, Cultured; D002645:Chickens / Q000293:injuries / Q000378:metabolism*; D003049:Coccidiostats / Q000009:adverse effects*; D003094:Collagen / Q000096:biosynthesis* / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005347:Fibroblasts / Q000187:drug effects; D008985:Monensin / Q000494:pharmacology; D009528:Nicarbazin / Q000494:pharmacology; D010880:Piperidines; D011799:Quinazolines / Q000009:adverse effects*; D052999:Quinazolinones; D011897:Random Allocation; D012867:Skin / Q000187:drug effects* / Q000293:injuries / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
D003049:Coccidiostats; D010880:Piperidines; D011799:Quinazolines; D052999:Quinazolinones; D009528:Nicarbazin; D003094:Collagen; D008985:Monensin; C010176:halofuginone